The study was designed as a single-site, parallel-group, three-arm superiority randomized controlled trial with a 1:1:1 allocation ratio. Sixty-six caregivers of cancer patients were randomly assigned to one of three conditions: a cognitive-behavioral stress management program, an acceptance and commitment therapy program, or a control group receiving no experimental intervention. Both active interventions were delivered in person and followed an identical structure of eight sessions, each lasting ninety minutes and conducted twice a week. That symmetry matters methodologically, because it ensures that any difference in outcomes between the two treatments could not be attributed to differences in dose, duration, or delivery format.

To measure the effects, participants in all three groups completed two validated instruments at three time points: before the intervention, immediately after it, and at a two-month follow-up. Quality of life was assessed with the Caregiver Quality of Life Index-Cancer, a scale developed specifically to capture the multidimensional burden experienced by family caregivers of cancer patients, including disruption, financial strain, and emotional distress. Fatigue was measured with the Multidimensional Fatigue Inventory, which evaluates the construct across several dimensions such as general fatigue, physical fatigue, mental fatigue, reduced motivation, and reduced activity. Both instruments have previously been psychometrically validated in Iranian samples, making them well suited to the study population.

The statistical analysis relied on multivariate analysis of covariance, a technique that allows researchers to compare multiple outcomes across groups simultaneously while controlling for pre-existing differences at baseline. The results showed a statistically significant difference in both quality of life and caregiver fatigue among the three groups at both the posttest and follow-up phases, with p values below 0.05. In plain terms, caregivers who received either active therapy reported better quality of life and less fatigue than those who received neither, and those benefits were still detectable two months after the sessions ended.

There was, however, one important nuance. In the cognitive-behavioral stress management group, the improvement in quality of life was not maintained at the two-month follow-up, whereas the fatigue benefits persisted. In the acceptance and commitment therapy group, both the quality-of-life gains and the fatigue reductions held up over the follow-up period. Even so, when the researchers directly compared the two interventions against each other, they found no statistically significant difference between them on either outcome. Both therapies beat the control condition, but neither could claim superiority over its rival.

The equivalence finding is scientifically interesting because the two therapies rest on quite different theoretical foundations. Cognitive-behavioral stress management, developed by Michael Antoni, Gail Ironson, and Neil Schneiderman, is an offshoot of classical cognitive-behavioral therapy that combines cognitive restructuring, coping skills training, relaxation techniques, and stress-management strategies. Its core logic is that caregivers suffer because distorted appraisals and ineffective coping amplify the stress response, and that teaching people to identify, challenge, and replace maladaptive thoughts while regulating physiological arousal will reduce both psychological distress and its somatic consequences, including exhaustion.

Acceptance and commitment therapy, introduced by Steven Hayes and colleagues in 1999, takes a fundamentally different route to the same destination. Rather than trying to change the content of difficult thoughts, ACT uses mindfulness, acceptance, cognitive defusion, and values clarification to change a person’s relationship to those thoughts. Caregivers are encouraged to notice painful feelings without struggling against them and to commit to actions guided by their deeper values, even in the presence of distress. A growing body of evidence, including a 2025 systematic review and meta-analysis in Scientific Reports on ACT for caregivers of people with cancer, has supported this approach, and recent randomized trials have shown ACT’s promise for fatigue interference in patients with metastatic breast cancer and advanced lung cancer.

The fact that these two mechanistically distinct interventions produced comparable outcomes speaks to a broader debate in psychotherapy research. Some researchers argue that common factors, such as therapeutic attention, structured support, group cohesion, and the simple experience of being seen and helped, drive much of the benefit across different therapy brands. Others maintain that specific techniques matter but often converge on similar functional outcomes. The present trial cannot adjudicate that debate definitively, but its null comparison between CBSM and ACT adds to a literature, including meta-analyses by Francisco Ruiz and trials by A-Tjak and colleagues, in which ACT and traditional cognitive-behavioral therapy repeatedly perform similarly across conditions ranging from depression to chronic illness.

Why should the equivalence result matter for caregivers in the real world? Family caregivers of cancer patients manage symptoms at home, coordinate treatment, absorb financial and emotional shocks, and frequently neglect their own health. Prior research has documented elevated fatigue, depression, anxiety, and diminished quality of life in this population, and caregiver fatigue has been proposed as a distinct clinical concept in nursing science. Yet caregivers are rarely the direct target of clinical services; the patient is. This trial suggests that relatively brief, structured psychological programs, eight sessions over four weeks, can produce measurable and partly durable improvements in caregivers’ daily functioning and wellbeing, which in turn may stabilize the care environment around the patient.

The durability question deserves attention. The finding that ACT’s quality-of-life gains persisted at two months while CBSM’s did not hints that acceptance-based and values-driven processes may support longer-term adaptation, even when short-term symptom relief is similar. It is a single trial with a modest sample of sixty-six participants at one site, so the difference in durability should be treated as preliminary rather than definitive, and the study was retrospectively registered at ClinicalTrials.gov under identifier NCT07329868. Still, the authors conclude that both ACT and CBSM offer a promising foundation for developing supportive and therapeutic programs aimed at improving the mental health of cancer caregivers. For health systems searching for scalable ways to care for the people who do the quiet work of caring, the message is encouraging: two well-tested psychological tools are now validated for the job, and clinicians may reasonably choose whichever fits their setting, their training, and the values of the families they serve.

Subject of Research: Comparing cognitive-behavioral stress management and acceptance and commitment therapy for quality of life and fatigue in caregivers of cancer patients

Article Title: A comparison of the efficacy of cognitive-behavioral stress management and acceptance and commitment therapy on the quality of life and fatigue of caregivers of patients with cancer: a randomized controlled trial

Article References: Hosseini, F. A.-S., Choobforoushzadeh, A., Mortazavizadeh, S. M. R., & Mirsaleh, Y. R. (2026). A comparison of the efficacy of cognitive-behavioral stress management and acceptance and commitment therapy on the quality of life and fatigue of caregivers of patients with cancer: a randomized controlled trial. Supportive Care in Cancer, 34(10), Article 1028. https://doi.org/10.1007/s00520-026-11205-9

Image Credits: AI Generated

DOI: 10.1007/s00520-026-11205-9

Keywords: cancer caregivers, acceptance and commitment therapy, cognitive-behavioral stress management, quality of life, fatigue, randomized controlled trial, psychotherapy, supportive care, mental health, clinical trial, comparison, efficacy

The trial compared 0.05 percent clobetasol propionate ointment, one of the strongest topical steroids in clinical use, with 0.1 percent tacrolimus ointment, a calcineurin inhibitor best known for treating atopic dermatitis. Twenty patients received each treatment. The question matters because early-stage mycosis fungoides is highly treatable with skin-directed therapies, yet the ideal first-choice agent has remained contested. Topical steroids are cheap, familiar, and fast, but long-term use carries the familiar toll of skin atrophy, striae, telangiectasia, and taper-dependent relapse. Tacrolimus offers a steroid-sparing alternative that suppresses T-cell activation without thinning the skin, but direct comparative evidence against clobetasol in lymphoma patients has been almost nonexistent until now.

On raw clearance rates, the verdict was lopsided. In the clobetasol group, 95 percent of patients achieved a complete clinical response, meaning their lesions resolved entirely, and the remaining 5 percent achieved a partial response. In the tacrolimus group, by contrast, only 60 percent reached complete clearance and 20 percent a partial response. The median time to complete response also favored the steroid, at two months versus three and a half months for tacrolimus, although that timing difference did not reach statistical significance. For clinicians and patients alike, the message of the first analysis is straightforward: clobetasol clears early patches and plaques faster and more often.

But the story changed when the researchers followed patients forward in time. Among those who achieved complete clearance, relapse occurred in 63.2 percent of the clobetasol-treated patients compared with just 25 percent of those treated with tacrolimus, a difference that approached but did not reach conventional statistical significance. Kaplan-Meier survival analysis, which tracks how long patients remain disease-free over months and years, showed a trend toward longer relapse-free survival in the tacrolimus group, with a log-rank p-value of 0.060. In a study of only forty patients, trends of this size are tantalizing rather than definitive, but they hint at a trade-off that clinicians have long suspected: steroids win the sprint while tacrolimus may hold ground longer in the marathon.

The biology behind that trade-off is worth unpacking. Mycosis fungoides is driven by clonal malignant T lymphocytes that home to the skin, and both drugs attack the inflammatory machinery these cells depend on, but by different routes. Clobetasol binds intracellular glucocorticoid receptors, broadly repressing transcription of inflammatory cytokines and inducing apoptosis in immune cells, a blunt but powerful instrument. Tacrolimus inhibits calcineurin, a phosphatase essential for activating the transcription factor NFAT in T cells, thereby blocking interleukin-2 production and T-cell proliferation with far greater selectivity. Because the steroid suppresses inflammation indiscriminately, it clears lesions dramatically, but once therapy stops or is tapered, the underlying malignant clone may rebound quickly. Calcineurin inhibition, gentler and more targeted, may leave residual disease control in place even as visible lesions fade more slowly.

Safety considerations sharpen the clinical calculus further. Prolonged use of super-potent steroids on thin skin, on the face, or in folds produces atrophy, striae, and secondary infection, and mycosis fungoides frequently affects these vulnerable sites and demands years of intermittent treatment. Tacrolimus ointment does not cause skin thinning, which is precisely why dermatologists have proposed it as a steroid-sparing option, and earlier work including a phase 2 trial of the related calcineurin inhibitor pimecrolimus published in The Lancet Haematology in 2022 demonstrated meaningful activity and tolerability in early-stage disease. One historical concern, a theoretical lymphoma risk from systemic absorption of calcineurin inhibitors, has been substantially allayed by large cohort studies such as the JOELLE investigations, which followed tens of thousands of users and found no convincing increase in lymphoma incidence, and pharmacokinetic studies showing minimal systemic exposure when tacrolimus is applied to intact skin.

The Istanbul team’s findings also sit within a growing evidence base for topical therapy in this lymphoma. Zackheim’s foundational work established patch-stage mycosis fungoides as responsive to potent topical corticosteroids, and a 2025 comparison from the same Turkish group, published in the Brazilian Annals of Dermatology, found clobetasol competitive with oral bexarotene in early disease. What has been missing is exactly the kind of direct steroid-versus-calcineurin-inhibitor comparison this study provides, even in retrospective form. The authors themselves caution that comparative data on topical therapies remain limited and that calcineurin inhibitors have been proposed as steroid-sparing alternatives largely on theoretical and indirect grounds.

The study’s limitations deserve honest weight. Forty patients divided into two groups of twenty, treated retrospectively rather than randomized, leave ample room for selection bias, confounding by disease severity or anatomical site, and underpowered statistics. Relapse definitions and follow-up duration are critical in a disease whose natural history is measured in decades, and differences that miss significance at p-values just above 0.05, as several here do, could easily prove real in a larger cohort or dissolve into noise. The authors do not claim that tacrolimus prevents relapse; they report trends. Still, in rare diseases, randomized trials are notoriously difficult to populate, and carefully collected comparative cohort data like this often guides practice for years before definitive evidence arrives.

For patients, the practical takeaway is a conversation rather than a prescription. Someone with extensive thin plaques on the face or flexures, or a history of steroid-induced skin damage, may reasonably begin with tacrolimus, accepting slower clearance and a somewhat lower chance of complete response in exchange for durability and skin preservation. Someone with thicker, widespread plaques and a need for rapid control may start with clobetasol, then consider rotating to or maintaining with a calcineurin inhibitor to hold the gains while sparing the skin. The pattern in this data, fast clearance with higher relapse on one side and slower, stickier remission on the other, maps neatly onto that sequential strategy, which many dermatologists already employ empirically.

What happens next is the familiar rhythm of clinical oncology: these findings need prospective confirmation, ideally in a randomized trial with standardized response criteria under the current ISCL-EORTC staging framework, longer follow-up to truly characterize relapse-free survival, and enough patients to convert suggestive p-values into conclusions. Until then, the Istanbul study earns its place as one of the few direct comparisons of the two most accessible topical treatments for early mycosis fungoides, and it reframes the question clinicians ask at the bedside. It is no longer simply which ointment clears the skin, but which ointment keeps it clear, and the answer may be that the humble immunomodulator cream, long relegated to second-line status, deserves a more prominent seat at the table for carefully selected patients facing this indolent lymphoma.

Subject of Research: Comparative efficacy of topical corticosteroid versus calcineurin inhibitor therapy in early-stage mycosis fungoides

Article Title: Comparison of the efficacy of topical 0.05% clobetasol propionate and topical 0.1% tacrolimus in the treatment of early-stage mycosis fungoides

Article References: Comparison of the efficacy of topical 0.05% clobetasol propionate and topical 0.1% tacrolimus in the treatment of early-stage mycosis fungoides. (n.d.). https://doi.org/10.1007/s00403-026-04958-0

Image Credits: AI Generated

DOI: 10.1007/s00403-026-04958-0

Keywords: mycosis fungoides, cutaneous T-cell lymphoma, clobetasol propionate, tacrolimus, topical therapy, dermatology, relapse-free survival, calcineurin inhibitors, skin-directed treatment, clinical research, Comparison, efficacy

The research tackles two questions that have long puzzled scholars of collective action. First, what psychologically differentiates people who participate in protest from those who share their opposition to democratic backsliding but remain on the sidelines? Second, why do some individuals participate more frequently or persistently than others once they have decided to act? These questions matter because democratic backsliding, the gradual dismantling of democratic institutions by elected leaders, has become one of the defining political phenomena of the past decade, and mass mobilization has repeatedly proven to be one of the few forces capable of halting it.

To answer these questions, Shultziner proposes what he calls a self-evaluative framework for collective action and inaction. The framework rests on three psychological pillars. The first is the perceived threat to one’s self-concept, the sense that the political situation endangers who you believe yourself to be and the values that define you. The second comprises self-esteem mechanisms, specifically the drive to avoid negative self-evaluations, such as the shame of standing by while one’s country slides toward autocracy, and the drive to maintain positive self-worth by acting in accordance with one’s moral identity. The third is efficacy perception, the classic belief that one’s actions can actually make a difference.

The empirical foundation of the study is unusually robust. It combines two studies conducted during a period of intense democratic crisis in Israel, where a sweeping judicial overhaul proposed in 2023 triggered one of the largest sustained protest movements in the country’s history. The first was an online survey of 1,135 respondents that directly compared protesters with non-protesters who opposed the government’s plan. The second was a field study of 1,514 participants that examined which psychological factors were associated with the duration and intensity of protest participation over time. This dual design allowed the researcher to test not only what pushes people into the streets in the first place, but what keeps them there.

The findings are nuanced and, in places, surprising. Comparing protesters to non-protesters, the study found that three factors consistently distinguished the two groups: the perceived threat to their self-concept, the role that protest occupied as a domain of self-esteem in their lives, and their perceptions of efficacy. People who saw the political crisis as an existential challenge to their identity, who experienced demonstrating as an expression of who they are, and who believed their participation mattered were significantly more likely to have joined the protests.

But when the analysis turned to participation intensity, how often and how persistently people protested, a different picture emerged. Perceived threat to the self-concept and self-esteem mechanisms were associated with how much people participated, yet efficacy perceptions were not. In other words, believing that the protest would succeed helped explain whether someone showed up at all, but it did not explain why some people returned dozens of times while others came once or twice. The people who sustained their involvement over months were those for whom protest had become tied to their sense of self-worth, a way of avoiding the corrosive feeling of complicity and of affirming their identity as people who stand up for democracy.

This dissociation between the predictors of participation and the predictors of persistence is among the study’s most consequential contributions. Much of the existing literature, including influential social identity models of collective action, treats participation as a relatively uniform outcome predicted by identity, grievance, and efficacy. The new findings suggest instead that getting people through the door and keeping them engaged are governed by partly distinct psychological processes. Movements that want to sustain momentum through long struggles against democratic erosion, the study implies, cannot rely solely on convincing supporters that victory is possible. They must also offer participants a domain in which their self-esteem is invested, a place where showing up feels like being one’s true self.

The theoretical stakes of this argument are considerable. Social identity theory and its descendants, such as the integrative social identity model of collective action, locate the engine of protest in identification with a group: people act collectively when their group identity is salient, when they perceive injustice against the group, and when they believe collective action is efficacious. Shultziner’s self-evaluative framework shifts the analytical focus from the group to the self. Threat here is not only or primarily a threat to the group’s status or existence, but a threat to the individual’s self-concept, and the motivational payoff of action is not only group advancement but the protection and enhancement of personal self-worth. The framework draws on long-standing psychological theory about self-discrepancy, self-affirmation, and the functions of self-esteem, applying these individual-level mechanisms to the collective arena.

The study’s context gives its findings particular weight. Israel’s 2023 protest movement against the judicial overhaul was remarkable for its scale, duration, and social breadth, drawing in sectors of society, including reserve military officers and high-tech workers, that rarely engage in mass protest. Surveys cited in the research indicate that a large majority of opponents to the legislation never attended a demonstration, making the country a natural laboratory for the protester-versus-non-protester comparison. The field study, conducted at protest sites, captured the variation in commitment among those who did attend, from occasional participants to those present at nearly every weekly demonstration. The research received ethics approval from the Jerusalem Multidisciplinary College and was funded by the institution, and the author reports no conflicts of interest.

Beyond its academic contributions, the study carries practical implications for anyone concerned with the defense of democracy. If self-esteem mechanisms sustain long-term participation, then movements under democratic backsliding should think carefully about how they frame participation: not merely as a strategic instrument with uncertain payoffs, but as a moral expression of personal identity whose psychological rewards are immediate and intrinsic, regardless of the political outcome. The research also helps explain a well-documented puzzle in civic engagement, the persistent gap between intention and behavior, by suggesting that many opponents of backsliding lack the self-conceptual stakes that convert private disapproval into public action. Understanding those stakes, the study argues, offers a unified way to comprehend both why people act and why they keep acting, and it opens a promising line of inquiry into the psychological foundations of democratic resilience at a moment when those foundations are being tested around the world.

Subject of Research: Psychological mechanisms of self-esteem and self-concept threat in collective action participation during democratic backsliding

Article Title: Self-evaluative framework for collective action and inaction: self-esteem mechanisms and participation intensity under democratic backsliding

Article References: Shultziner, D. (2026). Self-evaluative framework for collective action and inaction: self-esteem mechanisms and participation intensity under democratic backsliding. Current Psychology, 45(18), Article 1517. https://doi.org/10.1007/s12144-026-10072-1

Image Credits: AI Generated

DOI: 10.1007/s12144-026-10072-1

Keywords: collective action, democratic backsliding, self-esteem, protest, social movements, political psychology, self-concept, efficacy, social identity, participation intensity, Current Psychology, Israel protests

The magnitude of the time saving reported in the trial is striking. A mean venous anastomotic time of 8.1 minutes in the coupler group versus 19.2 minutes in the hand-sewn group represents a reduction of more than eleven minutes per venous repair, with a confidence interval indicating that the true saving lies between roughly ten and twelve minutes. In reconstructive procedures that often last several hours, this saving may appear modest, but its cumulative effect can be substantial. Shorter operative times are associated with reduced anesthesia exposure, lower costs, and potentially decreased risks of infection, thromboembolic events, and other perioperative complications, particularly in elderly patients or those with significant comorbidities undergoing lengthy oncologic reconstructions.

The mechanism by which the coupler achieves speed is worth understanding. The ring-pin device consists of two polyethylene rings with intraluminal pins; the vessel ends are passed through the rings and everted over the pins, which are then telescoped together. This produces an immediate, circumferential, intima-to-intima approximation without any suture material exposed to the bloodstream. By contrast, a hand-sewn anastomosis requires multiple interrupted sutures, each of which passes through the vessel wall and temporarily disrupts flow, creating opportunities for endothelial injury, mural thrombus formation, and turbulence. The theoretical hemodynamic advantage of the coupler, namely laminar flow across a smooth synthetic scaffold, has been supported by experimental studies of flow dynamics, although the clinical trial found no statistically significant difference in thrombosis rates between the techniques.

The reported thrombosis figures, 2.9 percent in the coupler group and 5.7 percent in the hand-sewn group, are consistent with the range of venous thrombosis rates reported across the broader microsurgical literature. The failure of this difference to reach statistical significance, with a p value of 0.68, should be interpreted cautiously. With seventy patients per arm, the trial was powered to detect a difference in anastomotic time, not in thrombosis or flap survival. Detecting a reliable difference in an event occurring at a rate of a few percent would require thousands of patients per group, as the authors themselves acknowledge. The absence of a statistically significant difference is therefore not evidence of equivalence, and clinicians should understand the trial as demonstrating a robust time advantage while leaving safety outcomes unresolved at the level of proof.

Complete flap survival exceeded 95 percent in both arms, reaffirming the overall reliability of contemporary free-tissue transfer. Success rates above 95 percent have become the expected standard in high-volume microsurgical units, and both techniques in this trial met that benchmark. The near-identical survival figures, 97.1 percent versus 95.7 percent, mirror the findings of prior systematic reviews and meta-analyses, which have generally concluded that coupler patency is at least comparable to hand-sewn patency in the venous circulation. Notably, the coupler has historically been considered less suitable for arterial anastomoses, particularly in smaller or thicker-walled arteries, which is why arterial repair remained hand-sewn throughout this study and why the findings apply specifically to the venous side of the microvascular circuit.

The observation that dual venous drainage was employed more frequently in the coupler group, 32.9 percent versus 18.6 percent, offers an interesting window into surgical decision-making. When a second venous anastomosis can be completed in approximately eight minutes rather than nearly twenty, surgeons may be more willing to invest in a second drainage pathway, particularly in flap types known to be vulnerable to venous congestion, such as those with large surface areas, deep inferior epigastric perforator flaps, or flaps draining into a single comitant vein. Although this difference did not reach statistical significance, it raises the possibility that the coupler changes not only how venous anastomoses are performed but how many are performed, a behavioral effect that could itself influence flap outcomes in ways the trial was not designed to detect.

The trial’s population spanned oncologic, traumatic, and infective indications across multiple anatomical sites, addressing a recognized gap in the literature, where much of the earlier evidence came from single-region series dominated by breast or head and neck reconstruction. This breadth improves the generalizability of the time-saving finding, since the coupler’s advantage in anastomotic speed is unlikely to be confined to one flap type. Nevertheless, the exclusion criteria, which barred severely irradiated recipient vessels, documented coagulopathy, advanced peripheral vascular disease, and poorly controlled diabetes, mean that the results apply to a relatively favorable vascular substrate. Whether the coupler performs equally well in calcified, irradiated, or friable veins, where hand-sewn repair allows more adaptive placement of sutures, remains an open question.

The requirement for recipient veins between 1 and 4 mm in diameter reflects the design limits of commercially available coupler sizes. Within this range, the device offers a standardized solution, but vessels outside it, whether exceptionally small calibre veins in pediatric or distal extremity reconstruction or larger veins in some trunk and breast reconstructions, fall outside the device’s scope. Surgeons adopting the technique must therefore maintain proficiency in hand-sewn repair as a fallback. The trial’s finding that no device-related mechanical failures occurred is reassuring, but mechanical failure of couplers, including ring fracture, pin dislodgement, and tearing of the everted vessel wall, has been described elsewhere and typically demands conversion to a hand-sewn anastomosis under time pressure.

The learning curve associated with each technique is another consideration. All anastomoses in the trial were performed by three consultant microsurgeons, each with more than five years of hand-sewn experience and more than two years of coupler experience, and each proficient in both methods. This deliberate standardization of operator expertise minimizes the confounding that has plagued observational comparisons, where coupler use often clusters among surgeons or units with particular case mixes. In less experienced hands, the coupler’s advantage may be even greater, because the device reduces the technical variability that disproportionately affects trainees; conversely, improper sizing or awkward vessel orientation can produce coupler-specific complications that careful hand-sewn technique would avoid.

The trial’s limitations merit transparent acknowledgment. Beyond the absence of prospective registry registration, which the authors themselves flag, the study employed per-protocol analysis after four post-randomization exclusions, a choice that preserves the integrity of the comparison between actual techniques but slightly weakens the intention-to-treat principle that guards against attrition bias in randomized trials. Because the excluded patients did not receive either intervention, the risk of bias here is likely small, but readers should recognize the distinction. Blinding was necessarily incomplete: surgeons could not be masked, patients were unaware of the technique, and blinded independent assessors evaluated postoperative outcomes, an arrangement that represents a reasonable compromise given the physical nature of the intervention.

From a health-systems perspective, the economic implications of an eleven-minute saving per venous anastomosis deserve attention. Operating theatre time is among the most expensive resources in surgical care, and microsurgical cases occupy theatres for extended periods. If the coupler shortens procedures without compromising outcomes, the cumulative savings across a high-volume reconstructive service could offset device costs, although a formal cost-effectiveness analysis would need to account for device pricing, failure and conversion rates, and the value of reclaimed theatre capacity. Such analyses remain scarce in the reconstructive literature and would be a natural next step for health services researchers.

The trial also contributes to a longer historical arc. Vascular coupling was first described by Nakayama and colleagues in 1962, and the modern ring-pin system refined that concept into a practical instrument. Yet adoption has been uneven across the international microsurgical community, with some units using couplers for nearly all venous anastomoses and others reserving them for selected cases or avoiding them entirely. Prospective randomized evidence of the kind now provided has been the missing ingredient in debates that have until now rested largely on retrospective series, registry data, and meta-analyses of heterogeneous observational studies.

For practicing reconstructive surgeons, the practical takeaway is nuanced. The coupler reliably shortens venous anastomosis, and no signal of harm emerged in this trial, but the study cannot exclude small differences in thrombosis or flap survival that only very large samples could detect. Surgeons should therefore weigh the time advantage against case-specific factors: vessel caliber and quality, the availability of appropriately sized couplers, the presence of size mismatch, surgeon experience, and the hemodynamic demands of the particular flap. In flaps at high risk of venous congestion, the ease of adding a second coupler-based drainage anastomosis may itself be a decisive advantage.

Future research directions follow naturally from this work. Multicenter randomized trials with large samples, or prospective registries with risk adjustment, could resolve the residual uncertainty around thrombosis and survival outcomes. Studies stratifying results by flap type, recipient site, vessel caliber, and radiation status would refine patient selection. Investigations into the hemodynamic behavior of coupled versus sewn anastomoses using intraoperative flow measurement or Doppler surveillance could clarify the mechanistic basis of any clinical differences. Until such evidence accumulates, this trial stands as the strongest prospective support to date for a simple proposition: that venous coupling is a practical, efficient, and apparently safe option for reducing operative time in free-flap reconstruction, provided surgeons retain the hand-sewn skills that remain the foundation of microvascular practice.

Subject of Research: Efficacy of venous coupler versus hand-sewn venous anastomosis in free-flap reconstruction: a single-centre randomized controlled trial

Article Title: Efficacy of venous coupler versus hand-sewn venous anastomosis in free-flap reconstruction: a single-centre randomized controlled trial

Article References: Haq, A., Singh, V. K., Sharma, S., Bhavana, K., Kumar, S., & Vishwadeep (2026). Efficacy of venous coupler versus hand-sewn venous anastomosis in free-flap reconstruction: a single-centre randomized controlled trial. BMC Plastic and Reconstructive Surgery, 2(1), Article 23. https://doi.org/10.1186/s44452-026-00036-6

Image Credits: AI Generated

DOI: 10.1186/s44452-026-00036-6

Keywords: Efficacy, venous, coupler, versus, hand-sewn, anastomosis, free-flap, reconstruction, single-centre, randomized, controlled, trial